Innovative drug heavyweight! Arvinas (ARVN.US) collaborates with Pfizer (PFE.US) to advance third-party commercialization of "ER Degrader for Breast Cancer."

According to the Zhitong Finance and Economics APP, the emerging American biotechnology power Arvinas (ARVN.US) and its partner pharmaceutical giant Pfizer (PFE.US) have decided to out-license the commercialization rights of the blockbuster innovative drug vepdagestrant - that is, they have decided to out-license the commercialization rights of the drug to external parties. This drug is an investigational estrogen receptor degrader (ER degrader) for breast cancer. Its approval application has been submitted to the US Food and Drug Administration (FDA) in June.